Form 4: Esperion Therapeutics CFO Sells Shares
Statement of Changes in Beneficial Ownership
Esperion Therapeutics, Inc. Chief Financial Officer, Benjamin Halladay, reported a sale of 10,773 shares of common stock on June 17, 2026, to cover tax obligations.
Summary
- Benjamin Halladay, Chief Financial Officer of Esperion Therapeutics, Inc., sold 10,773 shares of common stock on June 17, 2026.
- The sale was executed at a price of $3.155 per share.
- The shares were sold to satisfy tax obligations arising from vested restricted stock units.
- Following the transaction, Halladay beneficially owns 702,829 shares of common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as the stock sale is a routine transaction for tax settlement and does not indicate a change in the executive's confidence in the company's future.
Negatives
- Sale of company stock by a key executive, although for tax purposes, can sometimes be perceived negatively by the market.
Future Outlook
This filing does not contain forward-looking statements or guidance regarding the company's future performance.
Industry Context
StockSavvy.ai notes that Form 4 filings are routine disclosures for corporate insiders and typically reflect personal financial management rather than company performance. The sale by the CFO is for tax settlement, a common occurrence with equity compensation.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Benjamin Halladay granted a Limited Power of Attorney to Sheldon Koenig and Benjamin Looker to execute SEC forms on his behalf. | 11/16/2022 | Facilitates timely and accurate filing of required disclosures by authorized representatives. |
Stakeholder Impact
- Shareholders: The sale is for tax settlement and does not reflect a negative view of the company's prospects by the CFO, thus likely minimal impact.
Key Dates
| Date | Description |
|---|---|
| 11/16/2022 | Date of execution for the Limited Power of Attorney granted by Benjamin Halladay. |
| 06/17/2026 | Transaction date for the sale of common stock by Benjamin Halladay. |
| 06/18/2026 | Date of signature for the Form 4 filing. |
Keywords
Esperion Therapeutics, ESPR, Form 4, Insider Trading, Stock Sale, Benjamin Halladay, Chief Financial Officer, Tax Obligation, Restricted Stock Units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.